Abstract

Ex Vivo Percutaneous Absorption of Ketamine, Bupivacaine, Diclofenac, Gabapentin, Orphenadrine, and Pentoxyifylline: Comparison of Versatile Cream vs. Reference Cream

Author(s): Wang Xuexuan, Black Laura

Issue: Nov/Dec 2013 - Volume 17, Number 6

Page(s): 520-525

Download in electronic PDF format for $75
  • Ex Vivo Percutaneous Absorption of Ketamine, Bupivacaine, Diclofenac, Gabapentin, Orphenadrine, and Pentoxyifylline: Comparison of Versatile Cream vs. Reference Cream Page 1
  • Ex Vivo Percutaneous Absorption of Ketamine, Bupivacaine, Diclofenac, Gabapentin, Orphenadrine, and Pentoxyifylline: Comparison of Versatile Cream vs. Reference Cream Page 2
  • Ex Vivo Percutaneous Absorption of Ketamine, Bupivacaine, Diclofenac, Gabapentin, Orphenadrine, and Pentoxyifylline: Comparison of Versatile Cream vs. Reference Cream Page 3
  • Ex Vivo Percutaneous Absorption of Ketamine, Bupivacaine, Diclofenac, Gabapentin, Orphenadrine, and Pentoxyifylline: Comparison of Versatile Cream vs. Reference Cream Page 4
  • Ex Vivo Percutaneous Absorption of Ketamine, Bupivacaine, Diclofenac, Gabapentin, Orphenadrine, and Pentoxyifylline: Comparison of Versatile Cream vs. Reference Cream Page 5
  • Ex Vivo Percutaneous Absorption of Ketamine, Bupivacaine, Diclofenac, Gabapentin, Orphenadrine, and Pentoxyifylline: Comparison of Versatile Cream vs. Reference Cream Page 6

Abstract

This ex vivo human percutaneous absorption study evaluated a set of six model drugs (ketamine hydrochloride, bupivacaine hydrochloride, diclofenac sodium, gabapentin, orphenadrine citrate, pentoxifylline) from two popular formulations for topically applied compounding preparations. The compounded preparations used in this study were Versatile cream and a reference cream. Each formulation was applied to human trunk skin mounted on Franz Diffusion Cells, 50 mg/chamber (or 28.2 mg/cm2). Serial dermal receiver solutions were collected for 48 hours. Analysis of the resultant data supports the concept that the Versatile base formulation provides improved characteristics relative to the reference base. This is of key importance where the patient does not show clinical improvement when a conventional topical delivery vehicle is used in the formulation. From the results, it is reasonable to anticipate that, relative to the reference formulation, the Versatile formulation provides enhanced transdermal delivery of some analgesic medications

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy
Title/Author
(Click for Abstract / Details / Purchase)
Nov/Dec 2013
Pg. 520-525
May/Jun 2012
Pg. 248-252
Jul/Aug 2014
Pg. 332-340
May/Jun 2016
Pg. 231
Author(s): Allen Loyd V Jr
Mar/Apr 2024
Pg. 135
Author(s): Allen Loyd V Jr
May/Jun 2016
Pg. 250-256
Author(s): Trimble John, Light Bob
Jan/Feb 2002
Pg. 42
Author(s): Allen Loyd V Jr
Jan/Feb 2002
Pg. 70-73
Mar/Apr 2000
Pg. 133
Author(s): Allen Loyd V Jr
May/Jun 2003
Pg. 171
Author(s): Meece Jerry
May/Jun 2004
Pg. 185
Jul/Aug 2020
Pg. 320
Author(s): Allen Loyd V Jr
Jan/Feb 2012
Pg. 80-81
Author(s): Gupta Vishnu D
May/Jun 2012
Pg. 245
Author(s): Allen Loyd V Jr
Nov/Dec 2014
Pg. 504-511
Nov/Dec 2019
Pg. 496-503
Nov/Dec 2018
Pg. 466-468
Mar/Apr 2021
Pg. 146-155
Jul/Aug 2021
Pg. 336-343
Jan/Feb 2022
Pg. 55
Author(s): Allen Loyd V Jr